Evidence map›Paper›PMID 29024832›Full record

ArticleEuropean journal of medical genetics2018

Somatic second hit mutation of RASA1 in vascular endothelial cells in capillary malformation-arteriovenous malformation.

Philip E Lapinski, Abbas Doosti, Valerie Salato, Paula North, Patricia E Burrows, Philip D King

Open access · greenAbstract read
In one paragraph

Article in European journal of medical genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Capillary malformation-arteriovenous malformation syndrome (CM-AVM): a systematic review of cerebrovascular manifestations.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025
    Pooled it
  2. Guideline
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. The C2 domain augments Ras GTPase-activating protein catalytic activity.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Central conducting lymphatic anomaly: from bench to bedside.The Journal of clinical investigation · 2024
    Review
  13. Article
  14. Updates in Genetic Testing for Head and Neck Vascular Anomalies.Oral and maxillofacial surgery clinics of North America · 2024
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Philip E LapinskiDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48103, USA.
Abbas DoostiDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48103, USA.
Valerie SalatoDepartment of Pathology, Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, WI 53226, USA.
Paula NorthDepartment of Pathology, Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, WI 53226, USA.
Patricia E BurrowsDepartment of Radiology, Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, WI 53226, USA.
Philip D KingDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48103, USA. Electronic address: kingp@umich.edu.
Medical College of Wisconsin · USUniversity of Michigan–Ann Arbor · US

Funding

Ras-MAPK Regulation of Lymphatic Vessel Valve DevelopmentR01HL120888 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PHILIP D KING · 2015 to 2026
$4.6M
Random Monoallelic Expression and Human DiseaseR21HD078862 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KING, PHILIP D · 2014 to 2015
$428k
NHLBI NIH HHS R01 HL120888NICHD NIH HHS R21 HD078862
6 · The paper itself

Abstract

Capillary malformation-arteriovenous malformation (CM-AVM) is an autosomal dominant vascular disorder that is associated with inherited inactivating mutations of the RASA1 gene in the majority of cases. Characteristically, patients exhibit one or more focal cutaneous CM that may occur alone or together with AVM, arteriovenous fistulas or lymphatic vessel abnormalities. The focal nature and varying presentation of lesions has led to the hypothesis that somatic "second hit" inactivating mutations of RASA1 are necessary for disease development. In this study, we examined CM from four different CM-AVM patients for the presence of somatically acquired RASA1 mutations. All four patients were shown to possess inactivating heterozygous germline RASA1 mutations. In one of the patients, a somatic inactivating RASA1 mutation (c.1534C > T, p.Arg512*) was additionally identified in CM lesion tissue. The somatic RASA1 mutation was detected within endothelial cells specifically and was in trans with the germline RASA1 mutation. Together with the germline RASA1 mutation (c.2125C > T, p.Arg709*) in the same patient, the endothelial cell somatic RASA1 mutation likely contributed to lesion development. These studies provide the first clear evidence of the second hit model of CM-AVM pathogenesis.

Indexed as

AdolescentAdultArteriovenous MalformationsCapillariesChildEndothelial CellsEndothelium, VascularFemaleGerm-Line MutationHumansMalep120 GTPase Activating ProteinPort-Wine Stainp120 GTPase Activating ProteinRASA1 protein, humanArteriovenous malformationCapillary malformationEndothelial cellRASA1Somatic mutation

Identifiers

PMID29024832
PMCPMC5766414
OpenAlexW2762413087

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.